The art of glow... and glory
AstraZeneca (AZN.L) said on Thursday its Covid-19 antibody drug was 83 per cent effective in cutting the risk of people contracting symptomatic illness in a six-month follow-up study.
The results have cemented the drugmaker's lead in developing preventative coronavirus treatments.
The Anglo-Swedish company said a separate study in patients with mild-to-moderate Covid-19 showed that a higher dose of the therapy, AZD7442, cut the risk of symptoms worsening by 88 per cent when given within three days of first symptoms.
ALSO READ:
The latest round of positive results potentially position AstraZeneca as a rare supplier of both Covid-19 vaccines and treatments, with the drugmaker having said the therapy's "real advantage" was as a preventative shot, rather than as a treatment.
The art of glow... and glory
March being the World Endometriosis Awareness Month, we attempt to decode the not-so-widely understood condition that condemns its sufferers to a life of unbearable pain
UAE resident shares why she chose the 2020 Nissan Altima to be her road companion
Here are some landmarks that make the visit so much more worthwhile
Now calling a child or youngster “chubby” can be demeaning to them, for even an eight-year-old knows all about body-shaming
shashi tharoors world of words
When someone boasts he is “ahead of the curve”, in other words performing better, earlier or faster than the competition, that expression also has its roots in flying
The next twelve-month dividend yield is 5% with reference to IPO share price of Dh2.48 per share
Azam Nazeer Tarar says the decision was taken at a meeting between Prime Minister Shehbaz Sharif and Chief Justice of Pakistan Qazi Faez Isa